Cancer diagnostics company, Pacific Edge, has reported steady test volumes for the first quarter of the 2025 financial year.

In the three months to the end of June, the company processed 7,188 tests, which was a slight decrease of 0.3% compared to the previous quarter.

The decline in test volumes was primarily driven by the reduction in the company's direct sales team in the United States.

However, Pacific Edge also saw an acceleration of demand in New Zealand and sustained growth from Kaiser Permanente.

In the US, tests per ordering clinician increased to 6.8 in Q1 25, reflecting ongoing efficiency improvements and the impact of increased Kaiser Permanente volumes.

Asia-Pacific volumes, on the other hand, increased 15.5% to 1,283 tests, benefitting from higher demand in New Zealand and new regions in the South Island.

See more